ClinicalTrials.gg
Not yet recruitingNCT07136727GCOG-CG001Updated Aug 22, 2025

AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)

An interventional study of AI-assisted comprehensive management system in Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition), sponsored by The First Affiliated Hospital of Xinxiang Medical College. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by The First Affiliated Hospital of Xinxiang Medical College · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.

Planned enrollment
10th of 280
5,000 · median 143
Started
2025
with 44 others
No phase
118 of 417
27 open now
Primary completion
2027-05
later than 81 of 116 live
Registered
385th of 417
by date

Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 10th largest by planned enrollment of the 280 interventional ones that give a count, is one of 45 that started in 2025, is one of 118 with no phase, reaches primary completion later than 81 of the 116 other live ones, and was the 385th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Diabetes Mellitus with a site in China, or all of them as a file.
02

Study summary

Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.

Read the detailed description

The title of this study is"The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients with Comorbid Cancer: A prospective non-randomized controlled interventional study", to evaluate the impact of full-course management based on a multimodal digital fusion AI-assisted decision support system on the clinical outcomes of county-level oncologic comorbid patients through a prospective non-randomized controlled interventional study. The study plans to enroll 5,000 patients with pathologically confirmed malignancies and at least one comorbid condition (diabetes, hypertension, etc.) , in the first stage, the epidemiological characteristics of co-morbidity and its impact on prognosis, treatment response and quality of life were analyzed In the second phase, patients with comorbid pulmonary malignancies were selected to compare the clinical effects of the voluntary whole-process management group (including personalized intervention such as nutritional screening and dynamic monitoring) and the conventional treatment group, the third stage integrates multi-center Electronic Medical Records, genomic data, wearable device monitoring and other multi-modal data to construct an AI decision-making system, developing risk stratification, personalized treatment recommendation, and dynamic prognostic prediction models, finally, the differences in core indicators such as survival rate (PFS, OS) , complication control and medical resource efficiency between AI-assisted management and traditional mode were compared. This study realizes the integrated intervention of in-hospital and out-of-hospital through digital whole-process management, which is expected to provide an AI-driven precise decision support paradigm for primary medical institutions and improve the efficiency of comprehensive management of tumor comorbidity.

03

Conditions studied

  • Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition)

Keywords

  • Malignant neoplasm
  • Comorbidity
  • Artificial intelligence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a definite diagnosis of by histopathology and/or cytology;
  • Age ≥18 years;
  • There is no gender limit
  • Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;
  • Conscious and able to answer questions and use electronic devices autonomously;
  • Patients were able to understand the study and voluntarily sign an form;

Exclusion criteria

Exclusion Criteria:

  • Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;
  • With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;
  • Women during pregnancy or lactation;
  • Have participated in other interventional studies in the past 1 month or are currently participating;
  • Patients with ≥ 3 that do not respond to treatment;
  • Patients with an expected survival of \< 3 months that do not respond to treatment;
  • Cases deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    AI management unit

    For patients with comorbid pulmonary malignancies who have been included, the registration process is guided by the management platform. Researchers will use digital management throughout The platform carries out screening assessment and Comprehensive Evaluation of nutrition, exercise, psychology and symptoms of the subjects, and the system will be combined with the patient's disease and treatment Information, intelligent management of the whole project. The clinician can review the protocol in the light of the patient's disease status and give the full management instructions Case to patient side.

    Other: AI-assisted comprehensive management system

  • No intervention
    Standard Clinical Management

    Patients who are not willing to accept the whole program will only be followed up, and will receive standard clinical management without AI-assisted digital platform support. Patients will receive conventional treatment. In the data analysis phase, subjects were stratified to explore the feasibility and effectiveness of digital whole-course management in patients with oncological comorbidities.

Interventions

  • OtherAI-assisted comprehensive management system

    Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) : the time from randomization (or study enrollment) to the observation of disease progression or the occurrence of death from any cause. This period was assessed every 6-8 weeks using RECIST 1.1 criteria.

    Time frame: 24 months

  2. Overall survival (OS)

    Overall survival (OS) : the time from study enrollment to death from any cause from any cause, every 3 months during treatment, and every 3 months after the end of treatment. The patients were followed up at 6 months and the cause of death was recorded.

    Time frame: 24 months

Secondary outcomes

  1. Comorbidity control rate.

    Comorbidity control rate: the proportion of comorbidities achieving guideline-recommended control targets during the study period; stratified criteria should be established based on specific comorbidity types.

    Time frame: 24 months

  2. Quality of life(QLQ-C30).

    Quality of life: changes in scores at baseline, on-treatment, and follow-up were assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 scale, between-group differences

    Time frame: 24 months

  3. Medical resource consumption index.

    Medical resource consumption index: Comparing DRG-adjusted medical resource consumption indices between two groups.

    Time frame: 24 months

  4. Adherence to AI system interventions.

    Adherence to AI Interventions: 1. In-Hospital Rate - Percentage of inpatients completing AI-recommended actions (e.g., nutritional screening, real-time monitoring). 2. Out-of-Hospital Completion Rate: Percentage of discharged/outpatients adhering to AI-guided care (e.g., telehealth, wearable data tracking). Enables precise evaluation of AI-driven care across clinical settings.

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Publications

  • Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M, Cunningham C. Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015 Jul;26(7):1325-32. doi: 10.1093/annonc/mdv025. Epub 2015 Jan 20. PubMed 25605751 ↗
  • Ding R, Zhu D, He P, Ma Y, Chen Z, Shi X. Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China. BMC Cancer. 2020 Mar 24;20(1):250. doi: 10.1186/s12885-020-06759-8. PubMed 32209058 ↗
  • Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014 Sep;25(9):1821-1829. doi: 10.1093/annonc/mdu203. Epub 2014 Jun 10. PubMed 24915871 ↗
  • Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013 Nov 1;5(Suppl 1):3-29. doi: 10.2147/CLEP.S47150. PubMed 24227920 ↗
  • Jorgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012 Mar 27;106(7):1353-60. doi: 10.1038/bjc.2012.46. Epub 2012 Feb 21. PubMed 22353805 ↗
  • Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016 Jul;66(4):337-50. doi: 10.3322/caac.21342. Epub 2016 Feb 17. PubMed 26891458 ↗
  • Wedding U, Roehrig B, Klippstein A, Steiner P, Schaeffer T, Pientka L, Hoffken K. Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol. 2007 Mar;61(3):269-76. doi: 10.1016/j.critrevonc.2006.11.001. Epub 2007 Jan 4. PubMed 17207632 ↗
  • Abravan A, Faivre-Finn C, Gomes F, van Herk M, Price G. Comorbidity in patients with cancer treated at The Christie. Br J Cancer. 2024 Nov;131(8):1279-1289. doi: 10.1038/s41416-024-02838-w. Epub 2024 Sep 4. PubMed 39232185 ↗
  • Vrinzen CEJ, Delfgou L, Stadhouders N, Hermens RPMG, Merkx MAW, Bloemendal HJ, Jeurissen PPT. A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer. Cancer Res. 2023 Apr 4;83(7):1147-1157. doi: 10.1158/0008-5472.CAN-22-1336. PubMed 36779863 ↗
  • Siembida EJ, Smith AW, Potosky AL, Graves KD, Jensen RE. Examination of individual and multiple comorbid conditions and health-related quality of life in older cancer survivors. Qual Life Res. 2021 Apr;30(4):1119-1129. doi: 10.1007/s11136-020-02713-0. Epub 2021 Jan 14. PubMed 33447956 ↗
  • Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S, Allore H, Somerfield MR, Targia V, Extermann M, Cohen HJ, Hurria A, Holmes H. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016 Jul;7(4):249-57. doi: 10.1016/j.jgo.2015.12.002. Epub 2015 Dec 22. PubMed 26725537 ↗

Individual participant data

Plan to share: No — Data security and privacy protection measures.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for May 2027, 20 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 20 months is close to that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2025
First posted
Aug 22, 2025
StartEst.
Aug 15, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2031
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136727
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Aug 22, 2025

Study contacts

Wei Shen Wei Shen, MD, Doctor of Medicine
Contact
swccvsw@126.com
+86 15638800873
Ping Lu Ping Lu, MD, Doctor of Medicine
Contact
lupingdoctor@126.com
+86 13598722864
Wei Shen Wei Shen, MD, Doctor of Medicine
study chair · First Affiliated Hospital of Xinjiang Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion